Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Pharmaceutical maker Amgen will lower the sticker price of its cholesterol drug Repatha (generic: evolocumab) by 60% to $5,850 a year, it announced Wednesday. Repatha is a PCSK9 inhibitor shown to ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...

On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a ...

Amgen's cholesterol drug Repatha has a new use in Europe, as the company continues in its battle with Sanofi/Regeneron's rival therapy, Praluent. A PCSK9 inhibitor class drug, Repatha (evolocumab) is ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

Amgen has been trying since 2015 to protect its PCSK9 cholesterol drug Repatha by keeping Sanofi and Regeneron’s rival Praluent off the market, even going as far as to ask the U.S. Supreme Court to ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...

The agreement is based on the results from the FOURIER trial presented recently at the American College of Cardiology Scientific Sessions. In March, when cardiovascular outcomes results were presented ...

HOUSAND OAKS, Calif., Amgen today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with ...